Glenmark Pharma’s subsidiary Glenmark Specialty, has entered into an exclusive licensing agreement with Australia’s Seqirus to commercialize its nasal spray, Ryaltris in Australia and New Zealand.
Ryaltris is suggested for treating symptoms related with seasonal allergic rhinitis (SAR), in patients over 12 years of age. In a regulatory filing the company stated, “Under the terms of the agreement, Glenmark will be responsible for product supply and Seqirus will be responsible for regulatory filing and commercialization of the product in Australia and New Zealand.”
Further the company added that, it will receive an upfront payment as well as regulatory and commercial milestone payments from Seqirus.
